Drug Trial Radar · NCT03102606
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
May 29, 2018
Primary completion
Dec 12, 2018
Study completion Feb 8, 2021
Sponsor
- Lead sponsor
- BeyondSpring Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Covance; ICON plc
- First posted
- Apr 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed \>/= 1 but \< 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15. \*Study is officially closed on 08 Feb 2021\*
Conditions
- Chemotherapy-induced Neutropenia
Interventions
PlinabulinDrug
Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
PegfilgrastimDrug
PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Saline PlaceboOther
Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration
D5W PlaceboOther
Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Severe Neutropenia (DSN)Time frame: 21 Days
Locations
18 sites in 4 countries. Site status is shown where the registry gives one.
Stanford University School of Medicine - Cancer Institute
Stanford, California
Hematology/Oncology of the North Shore
Skokie, Illinois
Norton Cancer Institute
Louisville, Kentucky
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Linyi Cancer Hospital
Linyi, China
Liaoning Cancer Hospital & Institute
Shenyang, China
Henan Cancer Hospital
Zhengzhou, China
Heilongjiang Cancer Hospital
Harbin, Heilongjiang, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
State Budgetary Healthcare Institution of Stavropol Territory "Pyatigorsk Interregional Oncology Dispensary"
Pyatigorsk, Russia
SBI of Healthcare "Oncology Dispensary #2" Ministry of Healthcare of Krasnodar Region
Sochi, Russia
Volgograd Regional Clinical Oncology Dispensary
Volgograd, Russia
Dnipropetrovsk City Multifunctional Hospital
Dnipro, Ukraine
Prykarpatskiy Regional Oncological Center
Ivano-Frankivsk, Ukraine
Communal Institution of Kherson Regional Council "Kherson regional oncological dispensary"
Kherson, Ukraine
Kryvyi Rih Oncology Dispensary
Kryvyi Rih, Ukraine
Lviv State Oncological Regional Treatment and Preventive Center
Lviv, Ukraine
Municipal Institution "Sumy Regional Clinical Oncology Dispensary"
Sumy, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.